GH Research (GHRS) EBITDA (2020 - 2026)
GH Research (GHRS) posted quarterly EBITDA of -$16.7 million for Q4 2025, down 29.15% year-over-year from -$23.6 million in Q4 2024, and down 0.92% quarter-over-quarter from -$16.6 million in Q3 2025.
GH Research (GHRS) EBITDA (2020 - 2026) Analysis & Trends
GH Research's EBITDA history runs 6 years deep, the most recent figure standing at -$16.7 million for Q4 2025.
- In Q4 2025, EBITDA fell 29.15% year-over-year to -$16.7 million; the TTM figure through Dec 2025 stood at -$60.7 million (down 20.68% YoY), while the FY2025 annual figure was -$60.4 million, down 20.79% from the prior year.
- EBITDA for Q4 2025 stood at -$16.7 million, down from -$16.6 million in the prior quarter.
- The five-year high for EBITDA was -$1.1 million in Q1 2021, with the low at -$16.7 million in Q4 2025.
- The 5-year median for EBITDA is -$10.2 million (2023), against an average of -$9.9 million.
- The sharpest annual moves came in 2021 and 2025: EBITDA sank 7676.67% in 2021, then declined 10.44% in 2025.
- GH Research's EBITDA stood at -$6.6 million in 2021, then slumped by 38.53% to -$9.2 million in 2022, then decreased by 21.66% to -$11.2 million in 2023, then dropped by 16.0% to -$12.9 million in 2024, then slipped by 29.15% to -$16.7 million in 2025.
- Business Quant data shows GHRS's EBITDA at -$16.7 million in Q4 2025, -$16.6 million in Q3 2025, and -$14.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | -19.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.46 Mn |
| Dec 31, 2025 | -16.72 Mn |
| Sep 30, 2025 | -16.57 Mn |
| Jun 30, 2025 | -14.70 Mn |
| Mar 31, 2025 | -12.73 Mn |
| Dec 31, 2024 | -12.94 Mn |
| Sep 30, 2024 | -12.62 Mn |
| Jun 30, 2024 | -13.22 Mn |
| Mar 31, 2024 | -11.53 Mn |
| Dec 31, 2023 | -11.16 Mn |
| Sep 30, 2023 | -9.72 Mn |
| Jun 30, 2023 | -9.93 Mn |
| Mar 31, 2023 | -10.42 Mn |
| Dec 31, 2022 | -9.17 Mn |
| Sep 30, 2022 | -6.63 Mn |
| Jun 30, 2022 | -6.75 Mn |
| Mar 31, 2022 | -8.01 Mn |
| Dec 31, 2021 | -6.62 Mn |
| Sep 30, 2021 | -4.67 Mn |
| Jun 30, 2021 | -2.67 Mn |